+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Plasma Fractionation Market By Product (Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX), By Sector (Private Sector and Public Sector), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

  • PDF Icon

    Report

  • 68 Pages
  • April 2021
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5322524
The Europe Plasma Fractionation Market is expected to witness market growth of 9.3% CAGR during the forecast period (2021-2027).

Plasma fractionation refers to a separation method, which is adopted to extract plasma derivatives. There are various kinds of plasma derivatives accessible in the market such as albumin and immunoglobulins. These products have concentrated fractions of plasma protein, which is extracted with the help of fractionation of plasma collected from a huge number of donors. Moreover, plasma derivatives are utilized in various medical domains like critical care, neurology, and hematology. For example, immunoglobulins are employed in neurology in order to assist patients who are suffering from multiple sclerosis and neuropathic pain. Furthermore, these products are widely utilized in research labs and hospitals, due to the increasing awareness regarding their usage in several medical domains.

Immunoglobulins are utilized as first-line therapy for several hematologic, immunologic, and neurologic conditions. The primary & common usage of immunoglobulin therapy is considered useful for treating the primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being regarded for various neurological disorders, such as neuropathic pain, multiple sclerosis, and chronic fatigue syndrome.

In the past few years, the diagnosis rate of numerous immunological disorders has grown owing to technological developments. Additionally, increasing genetic research for characterizing and diagnosing immunodeficiency will grow the clinical requirement for immunoglobulins because of the higher number of diagnosed patients.

The Germany market dominated the Europe Public Sector Market by Country in 2020, thereby, achieving a market value of $579.9 Million by 2027. The UK market is exhibiting a CAGR of 8.9% during (2021 - 2027). Additionally, The France market is anticipated to witness a CAGR of 10.3% during (2021 - 2027).

Based on Product, the market is segmented into Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX. Based on Sector, the market is segmented into Private Sector and Public Sector. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.

Scope of the Study

Market Segments covered in the Report:

By Product
  • Immunoglobulins
  • Albumin
  • Coagulation factor VIII
  • Coagulation factor IX

By Sector
  • Private Sector
  • Public Sector

By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Grifols S.A.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Kedrion S.p.A
  • LFB S.A
  • Biotest AG (Tiancheng International Investment Limited)
  • Sanquin Blood Supply Foundation
  • Bio Products Laboratory Limited

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Plasma Fractionation Market, by Product
1.4.2 Europe Plasma Fractionation Market, by Sector
1.4.3 Europe Plasma Fractionation Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Plasma Fractionation Market by Product
3.1 Europe Immunoglobulins Market by Country
3.2 Europe Albumin Market by Country
3.3 Europe Coagulation factor VIII Market by Country
3.4 Europe Coagulation factor IX Market by Country
Chapter 4. Europe Plasma Fractionation Market by Sector
4.1 Europe Private Sector Market by Country
4.2 Europe Public Sector Market by Country
Chapter 5. Europe Plasma Fractionation Market by Country
5.1 Germany Plasma Fractionation Market
5.1.1 Germany Plasma Fractionation Market by Product
5.1.2 Germany Plasma Fractionation Market by Sector
5.2 UK Plasma Fractionation Market
5.2.1 UK Plasma Fractionation Market by Product
5.2.2 UK Plasma Fractionation Market by Sector
5.3 France Plasma Fractionation Market
5.3.1 France Plasma Fractionation Market by Product
5.3.2 France Plasma Fractionation Market by Sector
5.4 Russia Plasma Fractionation Market
5.4.1 Russia Plasma Fractionation Market by Product
5.4.2 Russia Plasma Fractionation Market by Sector
5.5 Spain Plasma Fractionation Market
5.5.1 Spain Plasma Fractionation Market by Product
5.5.2 Spain Plasma Fractionation Market by Sector
5.6 Italy Plasma Fractionation Market
5.6.1 Italy Plasma Fractionation Market by Product
5.6.2 Italy Plasma Fractionation Market by Sector
5.7 Rest of Europe Plasma Fractionation Market
5.7.1 Rest of Europe Plasma Fractionation Market by Product
5.7.2 Rest of Europe Plasma Fractionation Market by Sector
Chapter 6. Company Profiles
6.1 Emergent BioSolutions, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 CSL Limited
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Acquisition and Mergers:
6.3 Grifols S.A.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.1 Recent strategies and developments:
6.3.1.1 Acquisition and Mergers:
6.4 Octapharma AG
6.4.1 Company Overview
6.4.2 Recent strategies and developments:
6.4.2.1 Approvals:
6.4.2.2 Partnerships, Collaborations, and Agreements:
6.5 Takeda Pharmaceutical Company Limited
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expense
6.6 Kedrion S.p.A
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 LFB S.A.
6.7.1 Company Overview
6.8 Biotest AG (Tiancheng International Investment Limited)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Sanquin Blood Supply Foundation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Bio Products Laboratory Limited
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Product Launches and Product Expansions:

Companies Mentioned

  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Grifols S.A.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Kedrion S.p.A
  • LFB S.A
  • Biotest AG (Tiancheng International Investment Limited)
  • Sanquin Blood Supply Foundation
  • Bio Products Laboratory Limited

Methodology

Loading
LOADING...